PFP licenses FVIII technology to PT Bio Farma (Persero) of Indonesia for potential $1.36bn ASEAN-6 & India territoriesLearn More
According to the World Health Organisation (WHO) and the World Federation of Hemophilia around two thirds of the haemophilia patient population receive inadequate or no treatment at all.
PFP executives visit Bio Farma to kick start Tech Transfer process – January 2023
ProFactor Pharma’s executive directors, Jaymin Amin, CEO, and Richard Cruse, CFO, visited PT Bio Farma (Persero) (BFI) who recently licensed PFP’s patented process to make low-cost Factor VIII treatment for Haemophilia A. Jaymin met with BFI’s CEO, Mr. Honesti Basyir,...
Low-cost Haemophilia A treatment deal unlocks world of opportunity ￼
The patented process to make low-cost treatment for Haemophilia A, developed by Scottish biotechnology company ProFactor Pharma Ltd (PFP), has taken an important step closer to market. The successful completion of a Product Development, Technology Transfer and...